Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease

Authors

  • Brian T. Helfand,

    1. Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, and James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA
    Search for more papers by this author
  • Stacy Loeb,

    1. Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, and James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA
    Search for more papers by this author
  • Donghui Kan,

    1. Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, and James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA
    Search for more papers by this author
  • William J. Catalona

    1. Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, and James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA
    Search for more papers by this author

William J. Catalona, MD, 675 N. Saint Clair Street, Suite 20-150, Chicago, IL 60611, USA.
e-mail: wcatalona@nmff.org

Abstract

Study Type – Prognosis (case series)
Level of Evidence 4

OBJECTIVE

To determine whether the cumulative effects of five prostate cancer risk alleles (three single-nucleotide polymorphisms [SNPs] on chromosome 8Q24 and two SNPs on chromosome 17a) could help to identify possibly ‘insignificant’ disease.

MATERIALS AND METHODS

We genotyped 629 men of European ancestry who underwent radical prostatectomy at our institution between 2002 and 2007. Possibly ‘insignificant’ CaP was defined using the Ohori criteria (organ-confined, tumour volume <0.5 mL, Gleason pattern ≤4). Statistical analysis was used to compare patients with ‘insignificant’ and all other ‘significant’ cancer based upon genotype. Carrier status for the 5 SNPs were compared between patients with ‘insignificant’ disease and a separate population of 801 controls without CaP.

RESULTS

Overall, 38 (6.0%) patients with CaP met the Ohori criteria for ‘insignificant’ disease. Men with ‘significant’ cancer had a greater frequency of any of the five risk alleles than either patients with ‘insignificant’ disease or controls. None of the individual alleles genotyped on chromosomes 8 or 17 distinguished between ‘significant’ and ‘insignificant’ CaP. However, carriers of two or more risk alleles were more likely to have ‘significant’ disease.

CONCLUSIONS

Although no single risk allele distinguished ‘insignificant’ CaP, ‘insignificant’ disease was nearly three times as likely among carriers of ≤ one risk allele. Future studies are needed to further elucidate the cumulative relationship between CaP risk alleles and CaP aggressiveness.

Ancillary